Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Sees Significant Decline in Short Interest

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) was the target of a significant decline in short interest in December. As of December 31st, there was short interest totaling 73,076 shares, a decline of 29.7% from the December 15th total of 103,943 shares. Based on an average daily trading volume, of 86,065 shares, the days-to-cover ratio is currently 0.8 days. Approximately 5.5% of the company’s stock are sold short. Approximately 5.5% of the company’s stock are sold short. Based on an average daily trading volume, of 86,065 shares, the days-to-cover ratio is currently 0.8 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Two Sigma Investments LP purchased a new position in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 21,200 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. Two Sigma Investments LP owned approximately 1.28% of Galmed Pharmaceuticals at the end of the most recent reporting period. 76.14% of the stock is owned by institutional investors and hedge funds.

Galmed Pharmaceuticals Stock Down 1.6%

Shares of Galmed Pharmaceuticals stock traded down $0.01 during trading on Monday, reaching $0.77. The company’s stock had a trading volume of 80,028 shares, compared to its average volume of 75,579. The business has a 50 day moving average price of $0.93 and a 200-day moving average price of $1.33. Galmed Pharmaceuticals has a 12-month low of $0.73 and a 12-month high of $3.50. The company has a market capitalization of $1.27 million, a P/E ratio of -2.41 and a beta of 0.35.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a report on Wednesday, October 8th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Reduce”.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.